<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00524953</url>
  </required_header>
  <id_info>
    <org_study_id>UV-GVHD - HMO-CTIL</org_study_id>
    <nct_id>NCT00524953</nct_id>
  </id_info>
  <brief_title>Phase I Clinical Trial to Assess Safety of UV Phototherapy for the Prevention of GVHD Post Allogeneic SCT</brief_title>
  <official_title>Phase I - Clinical Trial to Assess Safety of Ultraviolet (UV) Phototherapy for the Prevention of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of thos study is to assess safety of Ultraviolet (UV) Phototherapy for the
      Prevention of Graft versus Host Disease after allogeneic stem cell transplantation (Phase I -
      Clinical trial). Following allogeneic BMT, patients will be placed on standard GVHD
      preventive therapy (cyclosporine).

      Secondary goals -

        -  monitoring immune system recovery

        -  the influence of stem cells origin on therapy and/orGVHD prevention

        -  the influence of UV-c treatment on survival

      clinical data and samples will be collected, during UV-c therapy, 100 days after discharge &amp;
      6 months after discharge - to examine the long-term effect of UV-c treatment on the patient's
      GVHD status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment will be given with a portable, easy to operate device named &quot;EUMATRON&quot;. this device
      contains a UV- lamp. 250 cc of blood from a peripheric vein is going through the device into
      a bottle with Low dose Heparin and returning to patient's body. procedure takes ~20 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability of UV-c phototherapy for the Prevention of Graft versus Host Disease after allogeneic stem cell transplantation</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>monitoring immune system recovery, influence on survival rates, influence of stem cells origin on treatment &amp; prevention of GVHD</measure>
    <time_frame>100 days, 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Allogeneic Transplantation (Non T-cell Depleted)</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients after allogeneic BMT (non T-depleted).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EUMATRON - EN 600 NT</intervention_name>
    <description>frequency - once a week, starting 4 days after transplantation for four weeks (total of 4 treatments) each treatment will last ~20 minutes. In addition - standard GVHD preventive protocol will be given to patients (including cyclosporine and steroids - if necessary)</description>
    <arm_group_label>I</arm_group_label>
    <other_name>EN 600 NT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients post non T cell depleted allogeneic stem cell transplantation

        Exclusion Criteria:

          -  morbidity unrelated to GVHD

          -  patients in an hemodynamic unstable condition

          -  acute uncontrolled bleeding

          -  patients undergoing dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reuven Or, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bone Marrow transplantation, cancer immunotherapy &amp; immunobiology research center, Hadassah University Hospital, Ein - Kerem, Jerusalem, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <last_update_submitted>June 10, 2015</last_update_submitted>
  <last_update_submitted_qc>June 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2015</last_update_posted>
  <keyword>allogeneic bone marrow transplantation</keyword>
  <keyword>non-T-cell depleted</keyword>
  <keyword>UV-c</keyword>
  <keyword>GVHD</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

